玻璃体腔注射康柏西普结合不同激光光凝时机在CRVO继发黄斑水肿患者中的应用效果分析  

Application Effect Analysis of Intravitreal Injection of Conbercept Combined with Different Laser Photocoagulation Timing for Patients with Macular Edema Secondary to CRVO

作　　者：解靖 李新章[1] 索南措[1] 张琼[1] 刘芳 JIE Jing;LI Xinzhang;SUO Nancuo;ZHANG Qiong;LIU Fang(Ophthalmology Department,Qinghai Red Cross Hospital,Xining,Qinghai,810000)

机构地区：[1]青海红十字医院眼科,青海西宁810000

出　　处：《智慧健康》2023年第12期195-199,共5页Smart Healthcare

摘　　要：目的 探究玻璃体腔注射康柏西普结合不同激光光凝时机在CRVO继发黄斑水肿患者中的应用效果。方法 选择本院2019年1月-2021年12月收治的100例CRVO继发黄斑水肿患者为研究对象,均采用玻璃体腔注射康柏西普治疗,依据不同激光光凝时机进行分组,分为研究组以及对照组各50例。对照组采用注射康柏西普后3d进行激光光凝治疗,以后1次/周治疗;研究组注射康柏西普后3d进行激光光凝治疗,第2、3个月重复治疗。观察两组患者最佳矫正视力(BCVA),黄斑中心凹厚度(CMT)以及炎症因子指标表达情况。结果 (1)研究组治疗有效率高于对照组(χ^(2)=5.316,P<0.05);(2)治疗前,两组患者BVCA,CMT指标数据比较差异不显著(P>0.05),治疗3个月以及治疗6个月后,研究组指标均低于对照组,差异有统计学意义(t=3.054/2.747/10.373/7.345,P<0.05);治疗前,两组患者VEGF,IL-6,IL-8指标数据比较差异不显著(P>0.05),治疗3个月以及治疗6个月后,研究组指标均低于对照组,差异显著(t=2.697、3.678、3.434、5.266、6.204、6.366,P<0.05);研究组并发症总发生率低于对照组(χ^(2)=4.891,P<0.05)。结论 在CRVO继发黄斑水肿患者治疗中,使用玻璃体腔注射康柏西普治疗后3d进行激光光凝治疗,并且在第2、3个月重复治疗,治疗效果较好,可校正患者视力,减少黄斑厚度,改善机体炎症指标,降低并发症发生率,有显著应用价值,值得在临床同病例患者疾病治疗中推广使用。Objective To investigate application effect of intravitreal injection of Conbercept combined with different laser photocoagulation timing for patients with macular edema secondary to CRVO.Methods The paper chose 100 patients with macular edema secondary to CRVO admitted to Qinghai Red Cross Hospital from January 2019 to December 2021 as study objects,treated with intravitreal injection of Conbercept,and divided them into study group and control group according to different laser photocoagulation times,with 50 cases in each group.Control group was treated wtih laser photocoagulation treatment 3 days after injection of Conbercept,followed by 1 dose per week of treatment,study group wtih laser photocoagulation treatment 3 days after injection of Conbercept and repeated treatment at 2 and 3 months.The best corrected visual acuity(BCVA),macular fovea thickness(CMT)and expression of inflammatory factor indicators was observed between two groups.Results①Effective rate of treatment in study group was higher than control group(χ^(2)=5.316,(P<0.05);②Before treatment,there was no significant difference in BVCA and CMT indicators between two groups(P>0.05).After 3 months of treatment and 6 months of treatment,indicators in study group were lower than control group,and difference was statistically significant(t=3.054/2.747/10.373/7.345,P<0.05).Before treatment,there was no significant difference in comparison of VEGF,IL-6 and IL-8 indicators between two groups(P>0.05).After 3 months of treatment and 6 months of treatment,indicators in study group were lower than control group,with significant difference(t=2.697/3.678/3.434/5.266/6.204/6.366,P<0.05).Total incidence of complications in study group was lower than control group(χ^(2)=4.891,P<0.05).Conclusion In treatment of patients with CRVO secondary macular edema,laser photocoagulation therapy can achieve good curative effect,which was carried on 3 days after intravitreal injection of Conbercept with repeated treatment in the second and third months.It can correct vision

关 键 词：玻璃体腔注射康柏西普法 激光光凝时机 CRVO继发黄斑水肿 应用效果 

分 类 号：R774[医药卫生—眼科]